Compoundeer Logo
COMPOUNDEER
Uncovering Potential
RankingCompaniesDCF
MEDP Logo

Medpace Holdings, Inc.

MEDP

Services-Commercial Physical & Biological Research

Mkt Cap

$12.13B

PE

42.93

Debt

$0

Cash

$245.4M

EV

$11.89B

FCF

$396.7M

Market Cap

$12.13B

P/E Ratio

42.93

Debt

$0

Cash

$245.4M

EV

$11.89B

FCF

$396.7M
Charts data: {"Earnings":[{"time":"2015-12-30","value":-8673000},{"time":"2016-12-30","value":13392000},{"time":"2017-12-30","value":39032000},{"time":"2018-12-30","value":72894000},{"time":"2019-12-30","value":100164000},{"time":"2020-12-30","value":144925000},{"time":"2021-12-30","value":181390000},{"time":"2022-12-30","value":245211000},{"time":"2023-12-30","value":282619000}],"Sales":[{"time":"2015-12-30","value":359059000},{"time":"2016-12-30","value":421582000},{"time":"2017-12-30","value":436152000},{"time":"2018-12-30","value":704589000},{"time":"2019-12-30","value":860969000},{"time":"2020-12-30","value":925925000},{"time":"2021-12-30","value":1142377000},{"time":"2022-12-30","value":1459996000},{"time":"2023-12-30","value":1885842000}],"Net Margins":[{"time":"2015-12-30","value":-0.02415480464213402},{"time":"2016-12-30","value":0.03176606211840164},{"time":"2017-12-30","value":0.0894917368256938},{"time":"2018-12-30","value":0.10345605736109988},{"time":"2019-12-30","value":0.11633868350660709},{"time":"2020-12-30","value":0.15651915651915652},{"time":"2021-12-30","value":0.15878295869051987},{"time":"2022-12-30","value":0.16795319987178048},{"time":"2023-12-30","value":0.1498635622708583}],"Assets":[{"time":"2015-12-30","value":984041000},{"time":"2016-12-30","value":979105000},{"time":"2017-12-30","value":950717000},{"time":"2018-12-30","value":967933000},{"time":"2019-12-30","value":1143071000},{"time":"2020-12-30","value":1390677000},{"time":"2021-12-30","value":1659935000},{"time":"2022-12-30","value":1352495000},{"time":"2023-12-30","value":1656828000}],"Stockholders Equity":[{"time":"2015-12-30","value":413474000},{"time":"2016-12-30","value":610710000},{"time":"2017-12-30","value":503530000},{"time":"2018-12-30","value":589703000},{"time":"2019-12-30","value":726283000},{"time":"2020-12-30","value":805779000},{"time":"2021-12-30","value":952928000},{"time":"2022-12-30","value":386387000},{"time":"2023-12-30","value":558950000}],"ROE":[{"time":"2015-12-30","value":-0.02097592593488345},{"time":"2016-12-30","value":0.02192857493736798},{"time":"2017-12-30","value":0.07751673187297678},{"time":"2018-12-30","value":0.12361137725261699},{"time":"2019-12-30","value":0.137913182602374},{"time":"2020-12-30","value":0.17985700793890136},{"time":"2021-12-30","value":0.1903501628664495},{"time":"2022-12-30","value":0.6346253885353286},{"time":"2023-12-30","value":0.5056248322748009}],"ROA":[{"time":"2015-12-30","value":0.020895470818797186},{"time":"2016-12-30","value":0.0536101848116392},{"time":"2017-12-30","value":0.06822009073152158},{"time":"2018-12-30","value":0.10439565548441886},{"time":"2019-12-30","value":0.11133429157068983},{"time":"2020-12-30","value":0.12118701898427887},{"time":"2021-12-30","value":0.12160235189932136},{"time":"2022-12-30","value":0.20913940532127662},{"time":"2023-12-30","value":0.20329509158464246}]}

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

Sector

  • CRL Logo

    CRL

  • INCY Logo

    INCY

  • IQV Logo

    IQV

  • MXCT Logo

    MXCT

  • NRC Logo

    NRC

  • OABI Logo

    OABI

Growth

%

%

Discount

%

%

Multiple

g\r+10%+11%+12%+13%+14%
0%109887
+1%1110988
+2%13111098
+3%141311109
+4%1714121110
Years012345678910TV
FCF$396.7M$500M$618.4M$750.4M$893.1M$1.042B$1.192B$1.335B$1.464B$1.571B$1.65B$16.5B
DCF$434.8M$467.6M$493.4M$510.7M$518.1M$515.2M$501.8M$478.5M$446.6M$407.8M$4.078B
Value$8.852B

In the chart Earnings are multiplied by this value.

Earnings Growth 54%
Earnings Stability 72%


Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12-201512-201612-201712-201812-201912-202012-202112-202212-2023TTM
Net Margin-2.4%3.2%8.9%10%12%16%16%17%15%15%
ROA2.1%5.4%6.8%10%11%12%12%21%20%20%
ROE-2.1%2.2%7.8%12%14%18%19%63%51%51%

What is the average Net Margin?

The average Net Margin over the past 5 years is +14.22%.

What is the trend of Net Margin?

The trend of Net Margin over the past 5 years is +1.11%.

What is the average Return on Assets (ROA)?

The average ROA over the past 5 years is +14.52%.

What is the trend of Return on Assets (ROA)?

The trend of ROA over the past 5 years is +2.25%.

What is the average Return on Equity (ROE)?

The average ROE over the past 5 years is +29.53%.

What is the trend of Return on Equity (ROE)?

The trend of ROE over the past 5 years is +9.74%.


Safety & Stabiliy

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12-201512-201612-201712-201812-201912-202012-202112-202212-2023TTM
Debt FCF4.912.272.790.570.00-0.000.140.000.00
Debt Equity0.940.290.470.140.00-0.000.130.000.00
MIN
Graham Stability---100%100%100%100%100%100%100%

What is the Debt/FCF?

The Debt/FCF trailing twelve month is 0.00.

What is the trend of Debt/FCF?

The trend of Debt/FCF over the past 5 years is -0.07.

What is the Graham’s Stability?

Graham’s Stability measure stands at 1.00.


Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12-201612-201812-202012-2022Trend
Revenue24%22%27%29%0.89%
Net Income55%31%25%15%-23%
Stockholders Equity-1.3%-1.1%-11%45%-2.9%
FCF26%23%20%13%1.3%

What is the 5 year Revenue CAGR?

The Revenue CAGR over the past 5 years is +21.76%.

What is the trend of Revenue growth?

The trend of Revenue growth rate over the past 5 years is +0.89%.

What is the 5 year Earnings CAGR?

The Earnings CAGR over the past 5 years is +31.13%.

What is the trend of Earnings growth?

The trend of Earnings growth rate over the past 5 years is -23%.

What is the 5 year Equity CAGR?

The Equity CAGR over the past 5 years is -1.07%.

What is the trend of Equity growth?

The trend of Equity growth rate over the past 5 years is -2.85%.

What is the 5 year FCF CAGR?

The FCF CAGR over the past 5 years is +23.06%.

What is the trend of FCF growth?

The trend of FCF growth rate over the past 5 years is +1.33%.